September 23, 2021 7:10pm
A scorecard of of 35 covered companies and date of releases (to date). The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status"
New addition: Applied Genetic Technologies (AGTC)
|
COMPANY |
SYMBOL | NET INCOME | Q2/21 LOSS | Q2/21 LPS | Q2/21 CASH | RUNWAY |
|---|---|---|---|---|---|---|
| Chinook Therapeutics | KDNY |
|
-$42.6 M | -$0.97 | $229.8 M | 2H/2023 |
| Alnylam Pharmaceuticals | ALNY | -$189.5 M | -$1.61 |
$1.9 B |
N/A | |
| Applied Genetic Technologies | AGTC |
-$12.1 M Year end: -$57.8
|
-$0.28 -$1.77
|
$107.1 M | Q1/23 | |
| Athersys, Inc. | ATHX | -$22.6 M | -$0.10 |
$56.7 M |
Q1/2023 | |
| Adverum Biotechnologies, Inc. | ADVM | -$44.3 M | -$0.45 |
$363.8 M |
2024 | |
| AxoGen, Inc. | AXGN | -$7.9 M |
-$0.19
|
$106.2 M | 2024 | |
| Bellicum Pharmaceuticals | BLCM |
|
-$2.2 M |
-$0.22 |
$21.8 M | 2022 |
| BioLife Solutions, Inc. | BLFS |
+$7.9 M or +$0.19 per share |
|
|
$76.3 M |
2024 |
| Biostage, Inc. | BSTG | -$382 K | -$0.04 |
$451 K |
Q2/2021 | |
| bluebird bio | BLUE Splits into two (2) companies | -$241.7 M | $3.58 |
$942 M |
2024 | |
| Brainstorm Cell Therapeutics | BCLI | -$6.3 M | -$0.17 |
$35 M |
1st H/2022 | |
| Caladrius Biosciences. | CLBS | -$5.68 M | -$0.10 |
$106.1 M |
2024 |
|
| Cellectis SA | CLLS |
|
-$40 M | -$0.88 |
$257 M |
2024 |
|
CRISPR Therapeutics
|
CRSP |
+$759.2 M or +$10.01 per share |
+$2.589.4 M | N/A | ||
|
Editas Medicine
|
EDIT | -$55.3 M | -$0.81 | $698.1 M | 2023 | |
| Fate Therapeutics |
FATE
|
-$54.9 M | -$0.58 | $845.1 M | 2024 | |
|
Global Blood Therapeutics
|
GBT | -$69.6 M | -$1.12 | $437.4 M | 2024 | |
|
Homology Medicine
|
FIXX | -$30.5 M | -$0.54 | $213.3 M | Q1/2023 | |
|
Intellia Therapeutics
|
NTLA | -$68.8 M | -$1.01 | $551 M | 2023 | |
|
Precigen formerly Intrexon Corporation |
PGEN | $41.9 M | -$0.21 | $200.4 M | 2H//2023 | |
| Ionis Pharmaceuticals | IONS |
|
-$81 M | -$0.57 | $2.1 B | N/A |
| Mesoblast Limited | MESO |
|
|
/20 | ||
| MiMedx Group, Inc |
MDXG |
|
-$1.8 M | -$0.08 | $85 M | 2023 |
| Pluristem Therapeutics, Inc. |
PSTI
|
Q1/2022 | ||||
| ReNeuron Group PLC |
RENE.L
|
|||||
| Regenxbio |
RGNX
|
-$57.6 M | -$1.36 | $530 M | 2H/2023 | |
| Sage Therapeutics |
SAGE
|
-$1.7.2 M | -$1.83 | $1.9B | N/A | |
| Sangamo Biosciences, Inc. |
SGMO
|
-$47.2 M | -$0.33 | $578.9 M | 2024 | |
| Solid Biosciences | SLDB |
-$18.7 M |
Not disclosed | $249 M | Q4/22 | |
| Stemline Therapeutics, Inc. | STML |
Acquired by Menarini, an Italian pharma |
||||
|
Ultragenyx
|
RARE | -$122.4 M | -$1.81 | $973.8 M | 2025 | |
|
uniQure N.V.
|
QURE |
Net income: +$399.5 M or +$8.68 per share |
|
$677.3 million | 1st Half/24 | |
|
Verastem, Inc.
|
VSTM | -$16.9 M | -$0.10 | $114.1 M | 2024 | |
|
Vericel Corporation
|
VCEL | -$3.8 M | -$0.08 | $116 M | 2024 | |
| Voyager Therapeutics | VYGR |
|
-$30.12 | -$0.80 | $143 M | Q2/2023 |
